Summarized by Masters of Longevity from Longevity Technology.
A news article about a biotech trial completing dosing for a regenerative macrophage cell therapy in advanced liver disease, previewing upcoming interim results and program plans.
Key Takeaways
- Resolution Therapeutics completed dosing the final patient in its EMERALD Phase I/II RTX001 trial for end-stage liver disease.
- Fifteen patients were treated in a multi-center, single-arm, open-label study across UK and Spain centers.
- Interim clinical data from the trial are expected in the fourth quarter of 2026, with a planned pivotal US study targeted for 2027.
